Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

20124,542 citationsJournal Articlebronze Open Access

Authors

Howard I. Scher · Memorial Sloan Kettering Cancer Center

Karim Fizazi · Institut Gustave Roussy

Fred Saad · Université de Montréal

Mary‐Ellen Taplin · Dana-Farber Cancer Institute

Cora N. Sternberg · Nini Hospital

Kurt Miller · Charité - Universitätsmedizin Berlin

Ronald de Wit ·

Abstract

Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy. (Funded by Medivation and Astellas Pharma Global Development; AFFIRM ClinicalTrials.gov number, NCT00974311.).

Topics & Keywords

Prostate Cancer Treatment and Research Cancer, Lipids, and Metabolism Prostate Cancer Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 367, Issue 13, pp. 1187-1197

DOI: 10.1056/nejmoa1207506

Field-Weighted Citation Impact: 287.36